You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Second-line chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent or Progressive Glioblastoma Trial in Detroit (Bevacizumab, Bevacizumab with chemo, Fractionated radiosurgery)

Completed
  • Recurrent or Progressive Glioblastoma
  • Detroit, Michigan
    Henry Ford Health System
Jan 30, 2023

NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Brain Neoplasms
  • (no location specified)
Dec 9, 2022

NSCLC Trial in New Haven, Farmington (KD019, Erlotinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • New Haven, Connecticut
  • +1 more
May 9, 2022

Pancreatic Tumors Trial (Tislelizumab)

Not yet recruiting
  • Pancreatic Neoplasms
  • (no location specified)
Dec 26, 2022

Advanced Gastric Adenocarcinoma Trial in Seoul (AZD1775, paclitaxel)

Completed
  • Advanced Gastric Adenocarcinoma
  • Seoul, Korea, Republic of
    Samsung Medical center
Jun 13, 2022

Pancreatic Cancer Trial in Milwaukee (First-line Chemotherapy, Second-line Chemotherapy, Chemoradiation)

Recruiting
  • Pancreatic Cancer
  • First-line Chemotherapy
  • +2 more
  • Milwaukee, Wisconsin
    Froedtert & the Medical College of Wisconsin
Jul 29, 2022

Ovarian Cancer Trial in Brazil (Palbociclib 125mg, Letrozole 2.5mg)

Active, not recruiting
  • Ovarian Cancer
  • Palbociclib 125mg
  • Letrozole 2.5mg
  • Belo Horizonte, Minas Gerais, Brazil
  • +4 more
Feb 10, 2022

Breast Cancer Trial in Detroit (biological, drug, other)

Terminated
Has Results
  • Breast Cancer
  • HER2Bi-armed activated T cells
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Nov 29, 2022

Recurrent Liver Cancer After Liver Transplantation Trial (Hepatic arterial infusion chemo + Atezolizumab and bevacizumab)

Not yet recruiting
  • Recurrent Liver Cancer After Liver Transplantation
  • Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
  • (no location specified)
Apr 17, 2023

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022

Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

Completed
  • Non-small Cell Lung Cancer
  • (no location specified)
May 8, 2023

Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)

Recruiting
  • Immunotherapy
  • Second-line Treatment
  • Guizhou, ZunYi, China
    The Second Affiliated Hospital of Zunyi Medical University
Jun 14, 2023

United States Using Electronic Medical Records to Assess

Completed
Has Results
  • Squamous Non-small Cell Lung Cancer
  • Second line (2L) afatinib
  • Second line chemotherapy
  • Dublin, Ohio
    Cardinal Health Specialty Solutions
Dec 22, 2021

Metastatic Gastric Adenocarcinoma, Second Line, Chemo Trial (nal-IRI /Experimental, Ramucirumab /Experimental,

Not yet recruiting
  • Metastatic Gastric Adenocarcinoma
  • +2 more
  • nal-IRI /Experimental
  • +2 more
  • (no location specified)
Jun 25, 2023

Neuroendocrine Tumor Trial in Beijing (PM8002, FOLFIRI)

Recruiting
  • Neuroendocrine Neoplasm
  • Beijing, China
    Chinese PLA General Hospital
May 25, 2023

Small Cell Lung Cancer, Angiogenesis, Chemo Effect Trial (Surufatinib, Irinotecan)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Nov 27, 2022

Gastric or Esophagogastric Junction Adenocarcinoma Trial (nimotuzumab plus paclitaxel, plus paclitaxel)

Not yet recruiting
  • Gastric or Esophagogastric Junction Adenocarcinoma
  • nimotuzumab plus paclitaxel
  • placebo plus paclitaxel
  • (no location specified)
Aug 3, 2023

Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer Trial in Boston (MRI)

Recruiting
  • Breast Cancer
  • +5 more
  • MRI
  • Boston, Massachusetts
    Brigham and Women's Hospital
Dec 9, 2022

Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,

Not yet recruiting
  • Pancreatic Acinar Cell Carcinoma
  • +6 more
  • Nab paclitaxel
  • +5 more
  • (no location specified)
Oct 30, 2023

SCLC Trial in Changchun (PM8002, Paclitaxel)

Recruiting
  • SCLC
  • Changchun, China
    Jilin Provincial Tumor Hospital
May 25, 2023

Metastatic Colorectal Cancer Trial in China (Fruquintinib+ chemo, Bevacizumab+ chemo)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Fruquintinib+ chemotherapy
  • Bevacizumab+ chemotherapy
  • Putian, Fujian, China
  • +11 more
Sep 27, 2022

Colorectal Cancer Trial in Hangzhou (Surufatinib, Toripalimab, chemo)

Recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    First affiliated hospital, Zhejiang University
Feb 26, 2022

Stomach Cancer Trial in Beijing (KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection)

Recruiting
  • Stomach Cancer
  • KN026/Placbo Injection
  • +3 more
  • Beijing, China
    Chinese PLA General Hospital
Jun 16, 2022

Esophagus Squamous Cell Carcinoma Trial in Beijing (Palbociclib, Afatinib)

Recruiting
  • Esophagus Squamous Cell Carcinoma
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
May 17, 2023

Esophageal Tumors Trial (Apatinib, The chemotherapeutic drug chosen by the investigator.)

Withdrawn
  • Esophageal Neoplasms
  • Apatinib
  • The chemotherapeutic drug chosen by the investigator.
  • (no location specified)
Apr 11, 2022